Stock Analysis on Net
Stock Analysis on Net

Abbott Laboratories (NYSE:ABT)

Analysis of Revenues

Microsoft Excel

Revenues as Reported

Abbott Laboratories, income statement, revenues

US$ in millions

Microsoft Excel
12 months ended: Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019
Established Pharmaceutical Products 5,066 4,912 4,718 4,303 4,486
Nutritional Products 8,154 7,459 8,294 7,647 7,409
Diagnostic Products 9,988 16,584 15,644 10,805 7,713
Medical Devices 16,887 14,687 14,367 11,787 12,239
Reportable segments 40,095 43,642 43,023 34,542 31,847
Other 14 11 52 66 57
Net sales to external customers 40,109 43,653 43,075 34,608 31,904

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

Item Description The company
Net sales to external customers Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). Abbott Laboratories net sales to external customers increased from 2021 to 2022 but then decreased significantly from 2022 to 2023.